{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:03:08Z","timestamp":1740106988973,"version":"3.37.3"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["417677437\/GRK2578"],"award-info":[{"award-number":["417677437\/GRK2578"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum D\u00fcsseldorf. Anstalt \u00f6ffentlichen Rechts"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>While antineoplastic therapies aim to specifically target cancer cells, they may also exert adverse effects on healthy tissues, like healthy hematopoietic stem and progenitor cells (HSPC), leading to hematotoxicity as a common side effect. Mesenchymal stromal cells (MSC) are a major component of the bone marrow (BM) microenvironment, regulating normal hematopoiesis, while their susceptibility to anticancer therapies and contribution to therapy-related hematotoxicity remains largely unexplored. To address this, we investigated the effects of etoposide, temozolomide, 5-azacitidine, and venetoclax on healthy BM-derived MSC functionality. Doses below therapeutic effects of etoposide (0.1\u20130.25\u00a0\u00b5M) inhibited cellular growth and induced cellular senescence in healthy MSC, accompanied by an increased mRNA expression of <jats:italic>CDKN1A<\/jats:italic>, decreased trilineage differentiation capacity, and insufficient hematopoietic support. Pharmacological doses of 5-azacitidine (2.5\u00a0\u00b5M) shifted MSC differentiation capacity by inhibiting osteogenic capacity but enhancing the chondrogenic lineage, as demonstrated by histochemical staining and on mRNA level. At the highest clinically relevant dose, neither venetoclax (40\u00a0nM) nor temozolomide (100\u00a0\u00b5M) exerted any effects on MSC but clearly inhibited cellular growth of cancer cell lines and primary healthy HSPC, pointing to damage to hematopoietic cells as a major driver of hematotoxicity of these two compounds. Our findings show that besides HSPC, also MSC are sensitive to certain antineoplastic agents, resulting in molecular and functional alterations that may contribute to therapy-related myelosuppression. Understanding these interactions could be helpful for the development of strategies to preserve BM MSC functionality during different kinds of anticancer therapies.<\/jats:p>","DOI":"10.1007\/s00204-024-03898-w","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T15:07:09Z","timestamp":1731424029000},"page":"393-406","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antineoplastic therapy affects the in vitro phenotype and functionality of healthy human bone marrow-derived mesenchymal stromal cells"],"prefix":"10.1007","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3738-4979","authenticated-orcid":false,"given":"Bo","family":"Scherer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucienne","family":"Bogun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annemarie","family":"Koch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Maus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karina S.","family":"Krings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Wesselborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Geyh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,12]]},"reference":[{"issue":"1","key":"3898_CR1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.it.2013.10.002","volume":"35","author":"BA Anthony","year":"2014","unstructured":"Anthony BA, Link DC (2014) Regulation of hematopoietic stem cells by bone marrow stromal cells. Trends Immunol 35(1):32\u201337. https:\/\/doi.org\/10.1016\/j.it.2013.10.002","journal-title":"Trends Immunol"},{"issue":"1","key":"3898_CR2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.5045\/br.2017.52.1.18","volume":"52","author":"YJ Bae","year":"2017","unstructured":"Bae YJ, Kwon YR, Kim HJ, Lee S, Kim YJ (2017) Enhanced differentiation of mesenchymal stromal cells by three-dimensional culture and azacitidine. Blood Res 52(1):18\u201324. https:\/\/doi.org\/10.5045\/br.2017.52.1.18","journal-title":"Blood Res"},{"issue":"8","key":"3898_CR3","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1158\/2159-8290.CD-22-0120","volume":"12","author":"EJM Bertrums","year":"2022","unstructured":"Bertrums EJM, Rosendahl Huber AKM, de Kanter JK et al (2022) Elevated mutational age in blood of children treated for cancer contributes to therapy-related myeloid neoplasms. Cancer Discov 12(8):1860\u20131872. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0120","journal-title":"Cancer Discov"},{"issue":"18","key":"3898_CR4","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.1158\/0008-5472.CAN-17-0282","volume":"77","author":"TD Bhagat","year":"2017","unstructured":"Bhagat TD, Chen S, Bartenstein M et al (2017) Epigenetically aberrant stroma in MDS propagates disease via Wnt\/beta-Catenin activation. Cancer Res 77(18):4846\u20134857. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0282","journal-title":"Cancer Res"},{"issue":"9","key":"3898_CR5","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41419-020-02972-2","volume":"11","author":"K Chen","year":"2020","unstructured":"Chen K, Yang Q, Zha J et al (2020) Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia. Cell Death Dis 11(9):778. https:\/\/doi.org\/10.1038\/s41419-020-02972-2","journal-title":"Cell Death Dis"},{"key":"3898_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14246065","author":"TC Chen","year":"2022","unstructured":"Chen TC, Minea RO, Swenson S, Yang Z, Thein TZ, Schonthal AH (2022) NEO212, a Perillyl alcohol-temozolomide conjugate, triggers macrophage differentiation of acute myeloid leukemia cells and blocks their tumorigenicity. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14246065","journal-title":"Cancers (Basel)"},{"issue":"2","key":"3898_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.6004\/jnccn.2008.0012","volume":"6","author":"J Crawford","year":"2008","unstructured":"Crawford J, Dale DC, Kuderer NM et al (2008) Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw 6(2):109\u2013118. https:\/\/doi.org\/10.6004\/jnccn.2008.0012","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"3898_CR8","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1182\/blood.V79.5.1291.1291","volume":"79","author":"D Delia","year":"1992","unstructured":"Delia D, Aiello A, Soligo D et al (1992) bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood 79(5):1291\u20131298. https:\/\/doi.org\/10.1182\/blood.V79.5.1291.1291","journal-title":"Blood"},{"issue":"2","key":"3898_CR9","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1158\/2159-8290.CD-16-0241","volume":"7","author":"M Demaria","year":"2017","unstructured":"Demaria M, O\u2019Leary MN, Chang J et al (2017) Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. Cancer Discov 7(2):165\u2013176. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0241","journal-title":"Cancer Discov"},{"key":"3898_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jpba.2013.11.010","volume":"90","author":"EJ Derissen","year":"2014","unstructured":"Derissen EJ, Hillebrand MJ, Rosing H et al (2014) Quantitative determination of azacitidine triphosphate in peripheral blood mononuclear cells using liquid chromatography coupled with high-resolution mass spectrometry. J Pharm Biomed Anal 90:7\u201314. https:\/\/doi.org\/10.1016\/j.jpba.2013.11.010","journal-title":"J Pharm Biomed Anal"},{"issue":"19","key":"3898_CR11","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1182\/blood.2022018244","volume":"141","author":"B Diamond","year":"2023","unstructured":"Diamond B, Ziccheddu B, Maclachlan K et al (2023) Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures. Blood 141(19):2359\u20132371. https:\/\/doi.org\/10.1182\/blood.2022018244","journal-title":"Blood"},{"key":"3898_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2020.114996","volume":"396","author":"HG Fakhrabadi","year":"2020","unstructured":"Fakhrabadi HG, Rabbani-Chadegani A, Ghadam P, Amiri S (2020) Protective effect of bleomycin on 5-azacitidine induced cytotoxicity and apoptosis in mice hematopoietic stem cells via Bcl-2\/Bax and HMGB1 signaling pathway. Toxicol Appl Pharmacol 396:114996. https:\/\/doi.org\/10.1016\/j.taap.2020.114996","journal-title":"Toxicol Appl Pharmacol"},{"key":"3898_CR13","first-page":"2585","volume":"6","author":"HS Friedmann","year":"2000","unstructured":"Friedmann HS, Kerby T, Calvert H (2000) Temozolomide and treatment of malignant glioma. Clin Cancer Res 6:2585\u20132597","journal-title":"Clin Cancer Res"},{"issue":"9","key":"3898_CR14","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1038\/leu.2013.193","volume":"27","author":"S Geyh","year":"2013","unstructured":"Geyh S, Oz S, Cadeddu RP et al (2013) Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells. Leukemia 27(9):1841\u20131851. https:\/\/doi.org\/10.1038\/leu.2013.193","journal-title":"Leukemia"},{"issue":"4","key":"3898_CR15","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s12015-020-09979-4","volume":"16","author":"A Halim","year":"2020","unstructured":"Halim A, Ariyanti AD, Luo Q, Song G (2020) Recent progress in engineering mesenchymal stem cell differentiation. Stem Cell Rev Rep 16(4):661\u2013674. https:\/\/doi.org\/10.1007\/s12015-020-09979-4","journal-title":"Stem Cell Rev Rep"},{"issue":"18","key":"3898_CR16","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1182\/blood.2020010163","volume":"138","author":"JS Hecker","year":"2021","unstructured":"Hecker JS, Hartmann L, Riviere J et al (2021) CHIP and hips: clonal hematopoiesis is common in patients undergoing hip arthroplasty and is associated with autoimmune disease. Blood 138(18):1727\u20131732. https:\/\/doi.org\/10.1182\/blood.2020010163","journal-title":"Blood"},{"issue":"9","key":"3898_CR17","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/stem.3387","volume":"39","author":"P Jager","year":"2021","unstructured":"Jager P, Geyh S, Twarock S et al (2021) Acute myeloid leukemia-induced functional inhibition of healthy CD34+ hematopoietic stem and progenitor cells. Stem Cells 39(9):1270\u20131284. https:\/\/doi.org\/10.1002\/stem.3387","journal-title":"Stem Cells"},{"key":"3898_CR18","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1634\/theoncologist.10-3-176","volume":"10","author":"E Kaminskas","year":"2005","unstructured":"Kaminskas E, Farrell AT, Wang Y-C, Sridhara R, Pazdur R (2005) FDA drug approval summary: azacitidine (5-azacytidine, VidazaTM) for injectable suspension. Oncologist 10:176\u2013182","journal-title":"Oncologist"},{"issue":"5","key":"3898_CR19","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/joim.13141","volume":"288","author":"JL Kirkland","year":"2020","unstructured":"Kirkland JL, Tchkonia T (2020) Senolytic drugs: from discovery to translation. J Intern Med 288(5):518\u2013536. https:\/\/doi.org\/10.1111\/joim.13141","journal-title":"J Intern Med"},{"issue":"3","key":"3898_CR20","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1365-2141.2004.05200.x","volume":"127","author":"J Li","year":"2004","unstructured":"Li J, Law HK, Lau YL, Chan GC (2004) Differential damage and recovery of human mesenchymal stem cells after exposure to chemotherapeutic agents. Br J Haematol 127(3):326\u2013334. https:\/\/doi.org\/10.1111\/j.1365-2141.2004.05200.x","journal-title":"Br J Haematol"},{"issue":"4 Suppl 8","key":"3898_CR21","first-page":"58","volume":"23","author":"AF List","year":"1996","unstructured":"List AF, Heaton R, Glinsmann-Gibson B, Capizzi RL (1996) Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity. Semin Oncol 23(4 Suppl 8):58\u201363","journal-title":"Semin Oncol"},{"issue":"1","key":"3898_CR22","doi-asserted-by":"publisher","first-page":"e0169921","DOI":"10.1371\/journal.pone.0169921","volume":"12","author":"J Lutzkendorf","year":"2017","unstructured":"Lutzkendorf J, Wieduwild E, Nerger K et al (2017) Resistance for genotoxic damage in mesenchymal stromal cells is increased by hypoxia but not generally dependent on p53-regulated cell cycle arrest. PLoS ONE 12(1):e0169921. https:\/\/doi.org\/10.1371\/journal.pone.0169921","journal-title":"PLoS ONE"},{"issue":"9","key":"3898_CR23","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrc.2017.60","volume":"17","author":"ME McNerney","year":"2017","unstructured":"McNerney ME, Godley LA, Le Beau MM (2017) Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer 17(9):513\u2013527. https:\/\/doi.org\/10.1038\/nrc.2017.60","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3898_CR24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00280-009-1015-8","volume":"65","author":"HJ Meany","year":"2009","unstructured":"Meany HJ, Warren KE, Fox E, Cole DE, Aikin AA, Balis FM (2009) Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors. Cancer Chemother Pharmacol 65(1):137\u2013142. https:\/\/doi.org\/10.1007\/s00280-009-1015-8","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7308","key":"3898_CR25","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/nature09262","volume":"466","author":"S Mendez-Ferrer","year":"2010","unstructured":"Mendez-Ferrer S, Michurina TV, Ferraro F et al (2010) Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 466(7308):829\u2013834. https:\/\/doi.org\/10.1038\/nature09262","journal-title":"Nature"},{"issue":"1","key":"3898_CR26","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1182\/blood.V81.1.151.151","volume":"81","author":"T Miyashita","year":"1993","unstructured":"Miyashita T, Reed JC (1993) Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81(1):151\u2013157. https:\/\/doi.org\/10.1182\/blood.V81.1.151.151","journal-title":"Blood"},{"key":"3898_CR27","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1590\/S0100-879X2005001000001","volume":"38","author":"K Neiva","year":"2005","unstructured":"Neiva K, Sun Y-X, Taichman RS (2005) The role of osteoblasts in regulating hematopoeitic stem cell activity and tumor metastasis. Braz J Med Biol Res 38:1449\u20131454","journal-title":"Braz J Med Biol Res"},{"issue":"1","key":"3898_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.canlet.2016.02.007","volume":"374","author":"NH Nicolay","year":"2016","unstructured":"Nicolay NH, Ruhle A, Perez RL et al (2016) Mesenchymal stem cells exhibit resistance to topoisomerase inhibition. Cancer Lett 374(1):75\u201384. https:\/\/doi.org\/10.1016\/j.canlet.2016.02.007","journal-title":"Cancer Lett"},{"issue":"2","key":"3898_CR29","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0022-1759(91)90198-o","volume":"139","author":"I Nicoletti","year":"1991","unstructured":"Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139(2):271\u2013279. https:\/\/doi.org\/10.1016\/0022-1759(91)90198-o","journal-title":"J Immunol Methods"},{"issue":"11","key":"3898_CR30","doi-asserted-by":"publisher","first-page":"3728","DOI":"10.1158\/1078-0432.CCR-03-0807","volume":"10","author":"S Ostermann","year":"2004","unstructured":"Ostermann S, Csajka C, Buclin T et al (2004) Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 10(11):3728\u20133736. https:\/\/doi.org\/10.1158\/1078-0432.CCR-03-0807","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3898_CR31","first-page":"341","volume":"2","author":"KE Pollok","year":"2003","unstructured":"Pollok KE (2003) In vivo protection of hematopoietic cells from alkylator-mediated DNA damage. Curr Hematol Rep 2(4):341\u2013347","journal-title":"Curr Hematol Rep"},{"issue":"9","key":"3898_CR32","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1042\/CBI20110637","volume":"36","author":"Z Qi","year":"2012","unstructured":"Qi Z, Zhang Y, Liu L, Guo X, Qin J, Cui G (2012) Mesenchymal stem cells derived from different origins have unique sensitivities to different chemotherapeutic agents. Cell Biol Int 36(9):857\u2013862. https:\/\/doi.org\/10.1042\/CBI20110637","journal-title":"Cell Biol Int"},{"issue":"7290","key":"3898_CR33","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/nature08851","volume":"464","author":"MH Raaijmakers","year":"2010","unstructured":"Raaijmakers MH, Mukherjee S, Guo S et al (2010) Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 464(7290):852\u2013857. https:\/\/doi.org\/10.1038\/nature08851","journal-title":"Nature"},{"issue":"1","key":"3898_CR34","first-page":"163","volume":"5","author":"JS Reese","year":"1999","unstructured":"Reese JS, Davis BM, Liu L, Gerson SL (1999) Simultaneous protection of G156A methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and sensitization of tumor cells using O6-benzylguanine and temozolomide. Clin Cancer Res 5(1):163\u2013169","journal-title":"Clin Cancer Res"},{"issue":"7","key":"3898_CR35","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1089\/scd.2010.0433","volume":"20","author":"AM Rosca","year":"2011","unstructured":"Rosca AM, Burlacu A (2011) Effect of 5-azacytidine: evidence for alteration of the multipotent ability of mesenchymal stem cells. Stem Cells Dev 20(7):1213\u20131221. https:\/\/doi.org\/10.1089\/scd.2010.0433","journal-title":"Stem Cells Dev"},{"issue":"11","key":"3898_CR36","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1002\/ijc.31619","volume":"143","author":"A Ruhle","year":"2018","unstructured":"Ruhle A, Huber PE, Saffrich R, Lopez Perez R, Nicolay NH (2018) The current understanding of mesenchymal stem cells as potential attenuators of chemotherapy-induced toxicity. Int J Cancer 143(11):2628\u20132639. https:\/\/doi.org\/10.1002\/ijc.31619","journal-title":"Int J Cancer"},{"issue":"1","key":"3898_CR37","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1006\/mthe.2000.0223","volume":"3","author":"N Sawai","year":"2001","unstructured":"Sawai N, Zhou S, Vanin EF, Houghton P, Brent TP, Sorrentino BP (2001) Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector. Mol Ther 3(1):78\u201387. https:\/\/doi.org\/10.1006\/mthe.2000.0223","journal-title":"Mol Ther"},{"key":"3898_CR38","doi-asserted-by":"publisher","first-page":"692497","DOI":"10.3389\/fonc.2021.692497","volume":"11","author":"Y Shi","year":"2021","unstructured":"Shi Y, Ye J, Yang Y et al (2021) The Basic Research of the Combinatorial Therapy of ABT-199 and Homoharringtonine on Acute Myeloid Leukemia. Front Oncol 11:692497. https:\/\/doi.org\/10.3389\/fonc.2021.692497","journal-title":"Front Oncol"},{"issue":"2","key":"3898_CR39","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/j.1875-9114.1984.tb03318.x","volume":"4","author":"JA Sinkule","year":"1984","unstructured":"Sinkule JA (1984) Etoposide: a semisynthetic epipodophyllotoxin. Chemistry, pharmacology, pharmacokinetics, adverse effects and use as an antineoplastic agent. Pharmacotherapy 4(2):61\u201373. https:\/\/doi.org\/10.1002\/j.1875-9114.1984.tb03318.x","journal-title":"Pharmacotherapy"},{"issue":"2","key":"3898_CR40","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER et al (2013) ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19(2):202\u2013208. https:\/\/doi.org\/10.1038\/nm.3048","journal-title":"Nat Med"},{"key":"3898_CR41","first-page":"44","volume":"1","author":"JE Stokes","year":"2012","unstructured":"Stokes JE, Bobola MS, Chamberlain MC, Silber JR (2012) Low leukocyte MGMT accompanies temozolomide induced myelotoxicity in brain tumor patients. J Cancer Res Updat 1:44\u201348","journal-title":"J Cancer Res Updat"},{"issue":"3","key":"3898_CR42","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1172\/JCI64098","volume":"123","author":"T Tchkonia","year":"2013","unstructured":"Tchkonia T, Zhu Y, van Deursen J, Campisi J, Kirkland JL (2013) Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest 123(3):966\u2013972. https:\/\/doi.org\/10.1172\/JCI64098","journal-title":"J Clin Invest"},{"key":"3898_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102261","volume":"99","author":"P Trillo Aliaga","year":"2021","unstructured":"Trillo Aliaga P, Spada F, Peveri G et al (2021) Should temozolomide be used on the basis of O(6)-methylguanine DNA methyltransferase status in patients with advanced neuroendocrine tumors? A systematic review and meta-analysis. Cancer Treat Rev 99:102261. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102261","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"3898_CR44","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41419-019-1407-6","volume":"10","author":"CFA Warren","year":"2019","unstructured":"Warren CFA, Wong-Brown MW, Bowden NA (2019) BCL-2 family isoforms in apoptosis and cancer. Cell Death Dis 10(3):177. https:\/\/doi.org\/10.1038\/s41419-019-1407-6","journal-title":"Cell Death Dis"},{"issue":"19","key":"3898_CR45","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1056\/NEJM198711053171904","volume":"317","author":"LM Weiss","year":"1987","unstructured":"Weiss LM, Warnke RA, Sklar J, Cleary ML (1987) Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med 317(19):1185\u20131189. https:\/\/doi.org\/10.1056\/NEJM198711053171904","journal-title":"N Engl J Med"},{"issue":"23","key":"3898_CR46","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1182\/bloodadvances.2018022053","volume":"2","author":"C Wenk","year":"2018","unstructured":"Wenk C, Garz AK, Grath S et al (2018) Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesis. Blood Adv 2(23):3447\u20133461. https:\/\/doi.org\/10.1182\/bloodadvances.2018022053","journal-title":"Blood Adv"},{"issue":"5","key":"3898_CR47","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/s41375-024-02226-6","volume":"38","author":"S Winter","year":"2024","unstructured":"Winter S, Gotze KS, Hecker JS et al (2024) Clonal hematopoiesis and its impact on the aging osteo-hematopoietic niche. Leukemia 38(5):936\u2013946. https:\/\/doi.org\/10.1038\/s41375-024-02226-6","journal-title":"Leukemia"},{"issue":"6","key":"3898_CR48","doi-asserted-by":"publisher","first-page":"e90846","DOI":"10.1371\/journal.pone.0090846","volume":"9","author":"X Yan","year":"2014","unstructured":"Yan X, Ehnert S, Culmes M et al (2014) 5-azacytidine improves the osteogenic differentiation potential of aged human adipose-derived mesenchymal stem cells by DNA demethylation. PLoS ONE 9(6):e90846. https:\/\/doi.org\/10.1371\/journal.pone.0090846","journal-title":"PLoS ONE"},{"issue":"1","key":"3898_CR49","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41536-021-00145-z","volume":"6","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Xin X, Wang L et al (2021) Senolytics improve bone forming potential of bone marrow mesenchymal stem cells from aged mice. NPJ Regen Med 6(1):34. https:\/\/doi.org\/10.1038\/s41536-021-00145-z","journal-title":"NPJ Regen Med"},{"key":"3898_CR50","doi-asserted-by":"crossref","unstructured":"Marrari A, Hornick JL, Ramaiya NH, Manola A, Wagner AJ (2011) Expression of MGMT and response to treatment with temozolomide in patients with leiomyosarcoma. Paper presented at the ASCO, Atlanta, Georgia, June 2\u20136, United States, 2011","DOI":"10.1200\/jco.2011.29.15_suppl.10074"},{"key":"3898_CR51","doi-asserted-by":"publisher","unstructured":"Scheffold A, Jebaraj BMC, Stilgenbauer S (2018) Venetoclax: targeting BCL2 in hematological cancers. recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer 212:215-242 https:\/\/doi.org\/10.1007\/978-3-319-91439-8_11","DOI":"10.1007\/978-3-319-91439-8_11"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-024-03898-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-024-03898-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-024-03898-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T17:27:44Z","timestamp":1737134864000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00204-024-03898-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,12]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["3898"],"URL":"https:\/\/doi.org\/10.1007\/s00204-024-03898-w","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"type":"print","value":"0340-5761"},{"type":"electronic","value":"1432-0738"}],"subject":[],"published":{"date-parts":[[2024,11,12]]},"assertion":[{"value":"1 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}